Clinicopathological and prognostic implications of endoglin (CD105) expression in hepatocellular carcinoma and its adjacent non-tumorous liver

Table 1 Correlation of IMVD-CD105 and IMVD-CD34 with clinicopathological parameters.

Clinical parameters	IMVD-CD105 (/0.74 mm2)				IMVD-CD34 (/0.74 mm2)
	n	mean	SD	P	n	mean	SD	P
Gender
Male	67	49.29	55.17	0.631	67	124.9	53.51	0.823
Female	19	56.19	54.4		19	128.1	53.54
Age (yr)
≤60 years	58	43.96	48.21	0.095	58	121.1	58.19	0.257
>60 years	28	65.01	64.99		28	135	40.39
HBsAg
Positive	69	46.35	49.36	0.121	69	121.5	53.02	0.227
Negative	17	70.08	73.87		17	139.4	52.48
Histopathological parameters
Tumor size
≤ 5 cm	33	65.9	58.98	0.043	33	147.8	53.41	0.002
>5 cm	53	41.42	50.26		53	111.9	48.68
Tumor encapsulation
Absent	53	48.31	48	0.497	53	120.3	54.19	0.193
Present	33	56.72	65.04		33	135.9	52.01
Venous invasion
Absent	44	64.17	60.96	0.02	44	133.6	50.14	0.157
Present	42	36.83	43.91		42	117.3	55.64
Microsatellite lesions
Absent	48	65.88	62.15	0.012	48	129.6	52.55	0.401
Present	38	35.06	41.02		38	119.7	52.53
Adjacent non-tumorous liver
Normal (0)	6	59.26	52.46	0.602 (0&1)	6	103	40.09	0.602 (0&1)
Chronic hepatitis (1)	38	43.14	57.47	0.817 (0&2)	38	118.4	47.69	0.118 (1&2)
Cirrhosis (2)	42	53.84	53.49	0.537 (1&2)	42	135.4	58.31	0.158 (0&2)
Edmonson grade
1 & 2	21	83.73	65.87	0.079	21	162.9	41.95	0.013
≥3	65	48.47	54.21		65	117.3	51.12
TNM stage
I & II	35	68.26	63.67	0.014	35	144.9	55.42	0.005
III & IVA	51	38.84	44.52		51	112.4	47.84

HBsAg, hepatitis B surface antigen; TNM, tumor-node-metastasis.